Dr. Med. Hans-Joachim Lanz Email & Phone Number

Munich, Bavaria, Germany

Retired pharmaceutical industry physician

Munich, Bavaria, Germany

Parsippany, NJ & Munich, Germany

Relocated from US (DSI) to Germany (DSE) and continue leading the global medical affairs function for edoxaban, a direct oral factor Xa inhibitor indicated for the prevention of stroke and systemic embolism in patients with atrial fibrillation and for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism.Edoxaban is.

Global medical lead for edoxaban, a novel factor Xa inhibitor anticoagulant in phase III clinical development for the prevention of stroke in patients with atrial fibrillation and the treatment and secondary prevention of venous thromboembolism (deep vein thrombosis, pulmonary embolism).

Leadership of Allergan's Clinical Operations, Biostatistics, Data Management and Programming, Clinical Quality and Training and Medical Writing departments. Building a Global Development Operations organization.

Leading Amgen’s US and Canada clinical site management organizations responsible for execution of the company’s development clinical trial programs (phase I-III) in North America. This organization includes clinical field operations (160 CRAs and managers), clinical operations management and clinical research services (study start up, contracts & budgets.

Leading Clinical R&D and Medical Affairs teams which develop new therapies for the treatment of cardiovascular and metabolic diseases. Additional leadership experience in Global Development Operations which manages clinical studies for the company across the R&D portfolio.

Berlin, Germany

Residency in Internal Medicine at the Free University Clinic in Berlin, Germany. Emergency medical care and cardiology focus, in addition endocrine and infectious diseases.Board certification in internal medicine 1988.